Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals

SIMPLE SUMMARY: Oral etoposide (VP16), an inhibitor of topoisomerase-II, has demonstrated clinical activity in metastatic breast cancer (MBC). To our knowledge, oral VP16 combined with trastuzumab (VP16-T) in HER2+ MBC has not been evaluated before. This combination is biologically relevant, as TOP2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalumeau, Clelia, Carton, Matthieu, Eeckhoutte, Alexandre, Ballet, Stelly, Vincent-Salomon, Anne, Vuagnat, Perrine, Bellesoeur, Audrey, Pierga, Jean-Yves, Stern, Marc-Henri, Bidard, Francois-Clement, Lerebours, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101021/
https://www.ncbi.nlm.nih.gov/pubmed/35565244
http://dx.doi.org/10.3390/cancers14092114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101021/
https://www.ncbi.nlm.nih.gov/pubmed/35565244
http://dx.doi.org/10.3390/cancers14092114

Ejemplares similares